Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
The discovery of rofecoxib, [MK 966, Vioxx (R), 4-(4 '-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor
Autore:
Prasit, P; Wang, Z; Brideau, C; Chan, CC; Charleson, S; Cromlish, W; Ethier, D; Evans, JF; Ford-Hutchinson, AW; Gauthier, JY; Gordon, R; Guay, J; Gresser, M; Kargman, S; Kennedy, B; Leblanc, Y; Leger, S; Mancini, J; ONeill, GP; Ouellet, M; Percival, MD; Perrier, H; Riendeau, D; Rodger, I; Tagari, P; Therien, M; Vickers, P; Wong, E; Xu, LJ; Young, RN; Zamboni, R; Boyce, S; Rupniak, N; Forrest, N; Visco, D; Patrick, D;
Indirizzi:
Merck Frosst Ctr Therapeut Res, Pointe Claire, PQ H9R 4P8, Canada Merck Frosst Ctr Therapeut Res Pointe Claire PQ Canada H9R 4P8 P8, Canada Merck Res Labs, Harlow, Essex, England Merck Res Labs Harlow Essex England rck Res Labs, Harlow, Essex, England Merck Res Labs, Rahway, NJ 07065 USA Merck Res Labs Rahway NJ USA 07065Merck Res Labs, Rahway, NJ 07065 USA Merck Res Labs, W Point, PA 19486 USA Merck Res Labs W Point PA USA 19486Merck Res Labs, W Point, PA 19486 USA
Titolo Testata:
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
fascicolo: 13, volume: 9, anno: 1999,
pagine: 1773 - 1778
SICI:
0960-894X(19990705)9:13<1773:TDOR[9>2.0.ZU;2-V
Fonte:
ISI
Lingua:
ENG
Soggetto:
PROSTAGLANDIN G/H SYNTHASE-1; BIOLOGICAL EVALUATION; SELECTIVE COX-2; COLON-CANCER; H SYNTHASE-2; EXPRESSION; 2,3-DIARYLTHIOPHENES; CELLS; RATS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
23
Recensione:
Indirizzi per estratti:
Indirizzo: Prasit, P Merck Frosst Ctr Therapeut Res, POB 1005, Pointe Claire, PQ H9R 4P8, Canada Merck Frosst Ctr Therapeut Res POB 1005 Pointe Claire PQ CanadaH9R 4P8
Citazione:
P. Prasit et al., "The discovery of rofecoxib, [MK 966, Vioxx (R), 4-(4 '-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor", BIOORG MED, 9(13), 1999, pp. 1773-1778

Abstract

The development of a COX-2 inhibitor rofecoxib (MK 966, Vioxx(R)) is described. It is essentially equipotent to indomethacin both in vitro and in vivo but without the ulcerogenic side effect due to COX-1 inhibition, (C) 1999Published by Elsevier Science Ltd. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 13/07/20 alle ore 16:59:07